Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial

Fig. 3The alternative text for this image may have been generated using AI.

Predictive biomarkers for potential response to Ld-IL2 treatment in RA. The percentage of regulatory T cells (Tregs) in CD4+ T cells and serum level of IL-21 in responders and non-responders (a, b). The correlation between percentage of Tregs and serum level of IL-2 (c). Heatmap showed a classification of the two groups (d). Each column represented an individual. Colors in the horizontal bar denoted the non-responder group (red) and the responder group (green). Tiles were colored based on clinical features, Tregs and serum cytokine levels, red and blue indicating high and low levels, respectively. Primary composition analysis (e). The non-responder group was shown in red, and the responder group was shown in green. PC1 and PC2 account for 39.8% and 14%, respectively, of the total variance. Panels d and e were performed by R 4.1.0 and R-packages (mixOmics and pheatmap) (http://www.metaboanalyst.ca). Data in graphs were mean ± SE. *P < 0.05

Back to article page